95 related articles for article (PubMed ID: 19473026)
1. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.
Ménard D; Niculescu-Duvaz I; Dijkstra HP; Niculescu-Duvaz D; Suijkerbuijk BM; Zambon A; Nourry A; Roman E; Davies L; Manne HA; Friedlos F; Kirk R; Whittaker S; Gill A; Taylor RD; Marais R; Springer CJ
J Med Chem; 2009 Jul; 52(13):3881-91. PubMed ID: 19473026
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Smalley KS; Flaherty KT
Future Oncol; 2009 Aug; 5(6):775-8. PubMed ID: 19663727
[TBL] [Abstract][Full Text] [Related]
3. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
Nourry A; Zambon A; Davies L; Niculescu-Duvaz I; Dijkstra HP; Ménard D; Gaulon C; Niculescu-Duvaz D; Suijkerbuijk BM; Friedlos F; Manne HA; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Mar; 53(5):1964-78. PubMed ID: 20148563
[TBL] [Abstract][Full Text] [Related]
4. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
[TBL] [Abstract][Full Text] [Related]
5. Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Zambon A; Ménard D; Suijkerbuijk BM; Niculescu-Duvaz I; Whittaker S; Niculescu-Duvaz D; Nourry A; Davies L; Manne HA; Lopes F; Preece N; Hedley D; Ogilvie LM; Kirk R; Marais R; Springer CJ
J Med Chem; 2010 Aug; 53(15):5639-55. PubMed ID: 20597484
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
[TBL] [Abstract][Full Text] [Related]
7. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
Niculescu-Duvaz D; Gaulon C; Dijkstra HP; Niculescu-Duvaz I; Zambon A; Ménard D; Suijkerbuijk BM; Nourry A; Davies L; Manne H; Friedlos F; Ogilvie L; Hedley D; Whittaker S; Kirk R; Gill A; Taylor RD; Raynaud FI; Moreno-Farre J; Marais R; Springer CJ
J Med Chem; 2009 Apr; 52(8):2255-64. PubMed ID: 19323560
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
J Med Chem; 2008 Jun; 51(11):3261-74. PubMed ID: 18473434
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.
Dong JJ; Li QS; Wang SF; Li CY; Zhao X; Qiu HY; Zhao MY; Zhu HL
Org Biomol Chem; 2013 Oct; 11(37):6328-37. PubMed ID: 23942809
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
Li QS; Li CY; Lu X; Zhang H; Zhu HL
Eur J Med Chem; 2012 Apr; 50():288-95. PubMed ID: 22361686
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents.
Li QS; Lv XH; Zhang YB; Dong JJ; Zhou WP; Yang Y; Zhu HL
Bioorg Med Chem Lett; 2012 Nov; 22(21):6596-601. PubMed ID: 23025996
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
17. Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Davies L; Pons JF; Whittaker S; Marais R; Springer CJ
Bioorg Med Chem; 2013 Mar; 21(5):1284-304. PubMed ID: 23376011
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel family of BRAF(V600E) inhibitors.
Qin J; Xie P; Ventocilla C; Zhou G; Vultur A; Chen Q; Liu Q; Herlyn M; Winkler J; Marmorstein R
J Med Chem; 2012 Jun; 55(11):5220-30. PubMed ID: 22537109
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
